Showing results (241-250 of 370) with videos related to

Sort By:
Pageof 37
Pharmacological Research|December 14, 2011
Anti-ischemic effects of multivalent dendrimeric A₃ adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heartBella Chanyshev, Asher Shainberg, Ahuva Isak, et al.
Journal of Medicinal Chemistry|September 20, 2002
Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundaryZhan-Guo Gao, Soo-Kyung Kim, Thibaud Biadatti, et al.
Nucleosides, Nucleotides & Nucleic Acids|April 12, 2008
Synthesis of 3'-acetamidoadenosine derivatives as potential A3 adenosine receptor agonistsMoon Woo Chun, Sung Wook Choi, Tae Kyung Kang, et al.
Nuclear Medicine and Biology|February 3, 2009
Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomographyDale O Kiesewetter, Lixin Lang, Ying Ma, et al.
Journal of Medicinal Chemistry|September 30, 2025
Bitopic A3 Adenosine Receptor Molecular Probes: Positive Allosteric Modulation and Noncanonical ActivationSiva Hariprasad Kurma, Matteo Pavan, Tina C Wan, et al.
Nucleosides, Nucleotides & Nucleic Acids|December 11, 2007
Synthesis of N6-substituted 3'-ureidoadenosine derivatives as highly potent agonists at the mutant A3 adenosine receptorLak Shin Jeong, Seung Ah Choe, Ae Yil Kim, et al.
Bioorganic & Medicinal Chemistry|October 7, 2004
Nucleotide analogues containing 2-oxa-bicyclo[2.2.1]heptane and l-alpha-threofuranosyl ring systems: interactions with P2Y receptorsMichihiro Ohno, Stefano Costanzi, Hak Sung Kim, et al.
International Journal of Oncology|March 14, 2018
CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiationZhi-Jie Wu, Xin Zhao, Lauren G Banaszak, et al.
Pageof 37